Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome
Condition(s) studied
Investigational drug(s) / intervention(s)
PCSK9 inhibitor: The aim is to improve blood lipid management by using atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg and PCSK9 inhibitors for 6-12 months
Study summary
sICASBLM is a prospective controlled trial, to asses the impact of improving blood lipid management on clinical outcome of moderate to severe symptomatic intracranial atherosclerotic stenosis patients (LDL-C\>1.8mmol/L) without endovascular therapy.
Eligibility
Primary outcome measure(s)
- Recurrent stroke — 6 months-12 months
the recurrent rate of clinical stroke
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Nanjing First Hospital, Nanjing Medical University | Nanjing | Jiangsu | Recruiting |
| Nanjing First Hospital | Nanjing | Jiangsu | Recruiting |
More Nanjing First Hospital, Nanjing Medical University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05397405 on ClinicalTrials.gov ↗ ← All trials in China